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Ablation
adrenalectomized rats 326
glomerular cell proliferation 297
intrarenal clusterin following 938
Acetate, vasorelaxant effects 166
Acid-base balance
intracellular proton buffering 43
potential, effect in calcium transport 289
vasorelaxant effect of acetate 166




contrast media induced 1008
dialysis (abst) 510
felodipine 36:S-94
nitroprusside, urodilatin, dopamine (abst) 493
ovarian carcinoma (abst) 1468
postischemic distribution, neutrophils (abst) 497
rhabdomyolysis (abst) 1451
vascular access (abst) 501
Acute tubular necrosis, Nephrology Forum 226
Acyclovir nephrotoxicity (abst) 484
Adenine dinucleotides, phospholipase (abst) 490
Adenosine
transport and metabolism 1143
triphosphate, proliferation, PGE2 (abst) 698
vasodilation, hypertensive kidney (abst) 1436
vasorelaxant effect of acetate 166
ADPKD 206
Adrenal steroids, sodium/excretion 37: S-97




sodium intake and excretion of rabbits 37:S-97
Adriamycin, glomerular epithelial cells (abst) 1432
Aging and sodium homeostasis 37:S-107
Alanine, cadmium toxicity (abst) 1451
Albumin
binding inhibition, CRF (abst) 480
excretion, diabetic glomerulopathy 741
excretion, pregnancy (abst) 1437
synthesis, nephrotic syndrome 132
Albuminuria
causes in NIDDM 758
endothelial dysfunction, NIDDM (abst) 1433
octreotide administration in diabetes 805




Alkalinization urinary (abst) 1462
Allograft
cyclosporine therapy (abst) 1460
disease confirmed by biopsy (abst) 1460
Epstein-Barr virus (abst) 1439
histopathology 155
noninvasive monitoring (abst) 1470
survival rates (abst) 1464
Allopurinol, renal ischemia (abst) 1451
Alport familial nephritis 1629
Aluminoxamine removal in dialysis 1400
Aluminum
accumulation/distribution, iron (abst) 1433
bone disease, deferoxamine (abst) 1470
bone disease, dialysis 1374





children with ESRD 1016
metabolism in CRF (abst) 1446
neurotransmitters, hypertension 37:S-2
Aminoglycoside administration, cytokines (abst) 1435
Aminopeptidases, glomerular epithelial cells 1571
Ammonia production from hippurate (abst) 484
Ammoniagenesis, cisplatin-induced alterations 73
Amphotericin B toxicity 1588
Amyloid nephrosis (abst) 1473
Amyloidosis
f32-microglobulin, cervical vertebrae 1646
132-microglobulin, dialysis (abst) 486
dialysis-related, Nephrology Forum 1416
Anemia
EPO therapy, CAPD/CCPD (abst) 504
EPO therapy, chronic renal failure (abst) 1464
EPO therapy, end-stage renal disease (abst) 1457
EPO therapy, impaired erythrocyte fluidity (abst) .... 506
Aneurysmal dilation, arterial hypertension 37:S-61
Angiotensin, urinary excretion (abst) 1435
Angiotensin converting enzyme (ACE) inhibition
ADPKD 206
arterial hypertension, diabetes 912
calcium channel blockers, diabetic nephropathy 904
diabetes, proteinuria (abst) 482
early diabetic nephropathy 883
exercise, proteinuria, IDDM (abst) 492





inhibition, mesangial cells (abst) 480
low-renin hypertension model 24
mesangial cells, IL-1/3, TNF-a (abst) 491
natriuresis on felodipine 36:S-73
PDGF-induced expression, protein kinase C (abst).... 484
phospholipase D, mesangial cells (abst) 490
protein synthesis, mesangial cells in vitro 124
vascular structure, blood pressure 37: S-S 1
Angiotensinogen gene expression in diabetes mellitus... 796
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disease, TGF-13 (abst) 1452
heparan sulfate antibody 115
nephritis (abst) 1430
Anti-mesangial cell antibodies (abst) 697
Anti-myeloperoxidase
PMN damage to endothelial cells 375
Anti-neutrophil cytoplasm antibodies (ANCA)
associated vasculitides (abst) 1442
glomerular inflammatory pathogenesis 375
idiopathic crescentic glomerulonephritis (abst) 1447
1gM, IgG and pulmonary hemorrhage 1304
vasculitis, HLA class II genes 1059
Anti-OKT3 antibody detection (abst) 509
Anti-tubular basement membrane disease (abst) 511
Antidiuretic hormone (abst) 483
Antihypertensive therapy
diabetic nephropathy 479 (abst), 904
diabetic rats 891
experimental diabetic nephropathy 898
Antioxidant enzymes, contrast media nephropathy .. .. 1008
Aortic aneurysm 37:S-61
Apoptosis in glomerulonephritis 607
Appetite and CAPD (abst) 503
Arginine vasopressin
NA transport regulation, CCD 255
oxytocin, in 3 cell lines (abst) 699
protein kinase C, Egr-1 mRNA induction (abst) 698
protein synthesis of MC in vitro 124






hemodiaffitration, tumor lysis syndrome (abst) 1467
Ascites, nephrogenic, children (abst) 1470
Atheromatosis, arterial SMC 37:S-87
Atherosclerotic vascular disease, hemodialysis (abst) . . . 480
Atrial natriuretic factor
aortic smooth muscle (abst) 699
localization 334
pathophysiology 1115
plasma concentration, calcium (abst) 1444
potassium channels, angiotensin II (abst) 494
Atrial natriuretic peptide (ANP)
cGMP production, inner medulla 37
insulin-dependent diabetes 813
kinetics in cardiac dysfunction 1333
Autosomal-dominant polycystic kidney disease
(ADPKD) 1311
Azoteniia, serum protein binding 1707
Basement membrane proteins 620
Beta blockers
early diabetic nephropathy 883
proteinuria reduction 1297
132-microglobulin
amyloidosis of cervical vertebrae 1646
synthesis 486
verapamil, CAPD, diabetic nephropathy (abst) 1459
Bicarbonate, in terminal RF 369
Biopsy
allograft kidney disease (abst) 1460
cyclosporine therapy (abst) 508
percutaneous with using semiautomated device (abst) . 485
transjugular 445
Bismuth, overdosage, renal damage (abst) 1432
Blood pressure
ambulatory, diabetes 847
angiotensin II, vascular structure 37:S-51
mineralocorticoid responsiveness (abst) 481
noninvasive continuous monitoring, dialysis (abst).... 478
regulation in ren-2 rats 37:S-l25
renal regulatory function (abst) 490
spectral analysis in uremia 37:S-l4
variability, cardiovascular risk 37:S-24




transplantation, loss of mass (abst) 509
transplantation, metabolism (abst) 507, 1456
transplantation, prednisone (abst) 508
transplantation (abst) 1441
Brain infarction (abst) 1462
Buffering capacity, intracellular proton and pH 43
Cadaver kidneys
evaluating donors (abst) 1471
recipient pool demographics (abst) 1467
Cadmium toxicity
magnesium depletion 1237
renal phosphate transport system (abst) 1451
Calcitriol, hyperparathyroidism hemodialysis (abst).... 1443
Calcium
ANF plasma concentration, CRF (abst) 1444
intracellular, vitamin D, mesangial cells (abst) 479
intracellular oscillations, collecting duct (abst) 1434
phosphate binding therapy, CRF (abst) 501
renal disease progression 36:S-2
vitamin D therapy, hemodialysis (abst) 501
Calcium antagonists
arterial hypertension, diabetes 912
chronic renal disease 36:S-1l4
renal function 36:S-66
renal hemodynamics, glomerular function 36: S-43
renal tubular effects 36:S-49
transplantation 36:S-87
Calcium beverages, stone-forming potential of 139
Calcium carbonate
phosphate binding, hemodialysis (abst) 1456
phosphate reduction, dialysis (abst) 502
Calcium channel blockers
ACE inhibition, diabetic nephropathy 904
captopril (abst) 1467
pH and potential, in calcium transport 289
renal perfusion flow (abst) 493
Calcium nephrolithiasis (abst) 1449
Calcium oxalate
crystallization, urate and GAGs 149
saturation, RDT patients, nephropathy (abst) 1445
Calcium transport
pH, calcium channel blockers 289
sodium interrelationship 281
CAPD
f32-microglobulin, verapamil (abst) 1459
catheter placement, peritonitis (abst) 1459
EPO therapy, peritoneal transport (abst) 1458
erythropoietin treatment (abst) 493
glucose and appetite (abst) 503
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HCV infection (abst) 483
hypercholesterolemia (abst) 1459
hyperlipidemia, gemfibrozil (abst) 1456
lymphatic absorption, trapping 1668
1 ,25(OH)D3, calcium (abst) 502
peritoneal catheter location (abst) 503
peritonitis (abst) 503
rHuEPO therapy (abst) 504
Safe Lock system (abst) 1463
toxic shock syndrome (abst) 1463
ultrafiltration, protein clearance (abst) 1436
Captopril
calcium channel blockers (abst) 1467
contrast media, renal function (abst) 1445
diabetic nephropathy (abst) 1466, 1473
long-term effect, uremia (abst) 1457
potassium plasma concentration (abst) 1457
prostaglandin production (abst) 512
Carbamylation alters LDL metabolism 1175
Carcinoma, renal cell, integrins 641





renal grafting (abst) 507
Cardiovascular role of central monoamine neurons.. . 37:S-8
Carnitine metabolism and chronic renal failure 1613
Carteolol, potassium plasma concentration (abst) 1457
Catecholamines and local anesthetics (abst) 479
C5b-9 complement proteins
glomerular mesangial cells (abst) 496
membranous nephropathy and C3dg 933
Cells
activation by IL-i 546
culturing renal 215
dendritic, immunophenotyping (abst) 489
development in kidney 657
graft-host migration, transplantation (abst) 488
plica type in proximal tubule (abst) 489
regulating oncogene proliferation (abst) 488
responses to ECM molecules 632
signaling by endothelin peptides 542
Cerebral regulation, thirst 37: S- 102
Cervical amyloidosis 1646
cGMP
metabolism in renal cells 88
production, ANP-stimulated 37
CGS 13080 in cyclosporine nephrotoxicity 199
Chloride transport in mTAL, PAF-induced inhibition
of 269
Cholesterol
hypertension, glomerular injury 1254
modulates proximal transport 983
Chronic hyponatremia 1662
Chronic purine aminonucleoside nephrosis (abst) 701
Chronic renal failure
albumin binding inhibition (abst) 480
anemia, EPO therapy (abst) 1464
calcium, ANF plasma concentration (abst) 1444
calcium acetate, phosphate binding therapy (abst) . .. . 501
carbamylation alters LDL metabolism 1175
carnitine metabolism 1613
children, sexual maturity (abst) 1471
enalapril (abst) 499
erythropoietin therapy (abst) 505
GH pituitary secretion 356
lipoprotein abnormalities, hemodialysis 1394
muscle protein, amino acid metabolism (abst) 1446
parathyroid hormone, phagocytosis 1501
survival rates (abst) 1456
tryptophan metabolism (abst) 1457
underweight patients, hemodialysis (abst) 1465
Cisplatin
nephrotoxicity 73
sulfonefluoresceine secretion (abst) 478
Clostridium difficile infection, uremia (abst) 503
Clusterin distribution in renal ablation 938
Collagen
production, glomerular mesangial cells (abst) .. 1452, 1462
type I DNA, tissue specific expression (abst) 706
type III glomerulopathy (abst) 1445
type IV gene transcription (abst) 706
Collecting duct
antigen localization (abst) 489
intracellular Ca, Na (abst) 1434
Complement activation
OKT3 treatment (abst) 1438
renal microcirculation (abst) 492
Conductivity method, post-dialysis dry weight 440
Confocal laserscan microscopy (abst) 1444
Contraluminal sulfate/oxalate exchanger (abst) 480
Contrast media as GFR markers (abst) 500
Cool temperature dialysate, LV function 961
Coronary artery disease, diabetic nephropathy (abst) ... 487
Cortex
epithelial, IL-8 production 191
epithelial cysts, human, in vitro 1222
monoclonal antibody to ganglioside 1638
Cortical collecting duct
fluoride flux 342
remnant kidney, response to AVP 1150
sodium channels, AVP, mineralocorticoids 255
Corticosteroids
ablative nephropathy, adrenalectomized rats 326
withdrawal, transplantation, children (abst) 1439
withdrawal, transplantation, cyclosporine (abst) 1440
Corticotropin-releasing factor, sodium intake 37:S-97
51Cr-EDTA clearance
glomerular filtration rate 1081, 1450 (abst)
IgA nephropathy (abst) 511
Cryoglobulins, IgG3, induced wire-loop lesions 65
Cuprophan dialyzer membrane (abst) 486
Cushing's syndrome 37:S-34
Cyclic-3',5'-nucleotide PDE isozymes 88
Cyclic AMP
erythropoietin mRNA regulation 1581
metabolism in renal cells 88
Cyclosporin
idiopathic membranous glomerulonephritis (abst). . .. 1438
IgA nephropathy (abst) 1452
Cyclosporine
diltiazem, transplantation (abst) 508
endothelin-l, mesangial cells 1713
felodipine, transplantation 36:S-82
isradipine, transplantation (abst) 507
laminin expression (abst) 705
nephrotoxicity.. 199, 484 (abst), 486 (abst), 487 (abst), 507
(abst), 1432 (abst)
nephrotoxicity, verapamil (abst) 1473
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proximal tubular cells (abst) 1451
renal biopsy changes (abst) 508
sodium retention 1599
steroid withdrawal, transplantation (abst) 1440
transplantation (abst) 1460
vascular responsiveness, renin (abst) 1451
Cysteinyl leukotrienes, renal synthesis 1543
Cystine urolithiasis, treatment (abst) 510
Cystinuria, 2-mercaptopropionyiglycine (abst) 510
Cysts
immunohistological origin (abst) 488
overexpressed c-myc in cpk mouse kidneys 317
renal cortex epithelial, in vitro 1222
Cytokines
aminoglycoside administration (abst) 1435
glomerulonephritis (abst) 497
hemodiàlysis, Nephrology Forum 683
interferon gamma, adhesion of PMN (abst) 696
NO synthase, steroids (abst) 697
paracrine, tubulointerstitial fibroblasts 14
Cytomegalovirus, graft rejection (abst) 489
Cytoskeleton of smooth muscle cells 37:S-87
Cytosolic redox state of NADHINAD+ 778
1,25 dihydroxycholecalciferol
glucose intolerance, hemodialysis 1049
1 ,25-dihydroxyvitamin D
in renal disease 161
1,25 dihydroxyvitamin D3
cellular immunity, hemodialysis (abst) 1470
1 ,25(OH)2D3
calcium therapy, CAPD (abst) 502
Deferoxamine, aluminum osteodystrophy (abst) 1470
Deflazacort therapy, transplantation (abst) 1439
Dendritic cells, immunophenotyping (abst) 489
Denmark, dialysis-associated hepatitis C (abst) 502
Dexamethasone (abst) 705
Diabetes
ACE inhibition, proteinuria (abst) 482
antihypertensive treatment (abst) 479
arterial hypertension 912
glornerular N-deacetylase 763
kallikrein, renin gene expression 789
KTAISPK transplant, renal failure 924
microalbuminuria, early glomerular disease 840
peritoneal clearances (abst) 1459
thromboxane /32 excretion (abst) 486
Diabetes, insulin dependent
exercise, ACE inhibitors (abst) 492
giomerular structure 741
glomerular thromboxane receptors 992
glonierular volume measurement 1085
glycemic control, renal function 920
microalbuminuria as prognostic indicator 836
natriuresis, ANP 813
nephropathy and hypertension 723, 736
plasma prorenin, microvascular disease (abst) 1437
sodium-lithium countertransport 855, 877
Diabetes, non-insulin dependent
albuminuria 758, 1433 (abst)
electron microscopy of glomeruli 749
survival rates 731
Diabetes insipidus
nephrogenic X-linked gene (abst) 1430
Diabetes mellitus
GFR, renal plasma flow, NIDDM 829
progressive renal disease 36:S-38
renin, angiotensinogen gene expression 796
streptozotocin-induced (abst) 700
tubular alteration, metabolic control (abst) 486
Diabetic glomeruloscierosis 396
Diabetic nephropathy
ACE inhibition, beta-blockers, diuretics 883
ACE inhibition, calcium channel blockers 904
ACE inhibition, GBM (abst) 484
antihypertensive therapy 499 (abst), 898
bone metabolism, transplantation (abst) 507
CAPD, 32-microglobulin, verapamil (abst) 1459
captopril (abst) 1466, 1473
clinical study (abst) 1448
coronary artery disease (abst) 487
cytosolic ratio of NADH/NAD 778
erythrocyte NaLi countertransport 862
glomerular basement membrane (abst) 703
glomerular hyperfiltration 822, 1620
glycemic control, Oslo study 920
heparan sulfate expression (abst) 1432
heparin sulfate proteoglycans 1070
hypertension 723, 736
inheritance 719
LDL binding to mesangial cells 1161
lipids, cellular Na/H antiport activity 872
lipids, lipoproteins, apolipoprotein (abst) 1449
NIDDM patients (abst) 1448
peripheral nerve conduction (abst) 1449
platelet activating factor (abst) 491
proteolytic lysosomal enzymes, hypertrophy 966
streptozotocin induced 768
transplantation (abst) 509
Diacylglycerol, ECM synthesis (abst) 700
Dialy sate, cool temperature, LV function 961
Dialysis
acute renal failure (abst) 510
amyloidosis, Nephrology Forum 1416
calcium carbonate, phosphate reduction (abst) 502
continuous noninvasive BP monitoring (abst) 478
cytokine production, Nephrology Forum 683
erythropoietin pharinokinetics (abst) 482
granulocyte LAM-I, MAC-i modulation 388
sodium balance, monitoring (abst) 1444
sports as rehabilitation (abst) 488
Dietary protein
ablative nephropathy 326
chronic transplant rejection 183
hyperfiltration 1620
renin, subtotal nephrectomy (abst) 496
Dietary salt as cardiovascular risk factor 37:S-90
Dietary sodium and elderly 37:S-l07
Diltiazem, transplantation (abst) 508
Distal tubule, calcium transport 281
Diuretics
early diabetic nephropathy 883
thiazide, PAH transport system (abst) 478
Dopamine
endogenous, renal function (abst) 481
renal hemodynamics (abst) 1445
renal sympathetic nerves (abst) 491
Dry weight, post-dialysis, measurement 440
Dyslipoproteinemia, renal failure (abst) 499
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Echocardiography, hemodialysis, rHuEPO therapy
(abst) 1469
Egr transcription factors 550
Eicosanoids
mesangial proliferation 554
production and protein uptake 1000
Electron microscopy 749
Electronic data processing in renal units (abst) 513
Enalapril
chronic nephropathy (abst) 499
compared with felodipine 36:S-78




children and nutrition 1016
diabetes and hemodialysis (abst) 1448
essential hypertension 36:S-33
morphological study (abst) 499
Endothelial cells
anti-MPO-stimulated PMN damage 375
lymphocyte adhesion (abst) 705
matrix modulation of 560
Endothelin
cytosolic calcium, L-arginine (abst) 695
infrarenal aortic cross clamping (abst) 1443
peptides 542
plasma levels, Korean hemorrhagic fever (abst) 1455
Endothelin- 1




in renal function 403
Endotoxin-induced renal failure (abst) 498
Enteric hyperoxaluria (abst) 512
Enzymes and regulation of sodium balance 37:S-1l4
Epithelial cells
cortical, IL-8 production in 191
development 657
IL-6, GM-CSF and PDGF-B (abst) 482
laminin, fibronectin (abst) 701
LLC-PK1, cyclic-3',5'-nucleotide PDE 88
magnesium, cadmium toxicity 1237
morphogenesis and tenascin 629
osteonectin expression 56




sodium-lithium countertransport (abst) 1442
Erythropoietin
age-dependent production (abst) 481
ambulatory peritoneal dialysis (abst) 505
anemia, CRF (abst) 1464
anemia, erythrocyte fluidity (abst) 506
anemia, hemodialysis (abst) 506
anemia, pre-dialysis renal hemodynamics 384
antithrombin III, fibrinogen, protein C (abst) 1471
CAPD (abst) 493
chronic renal failure (abst) 505
dialysis (abst) 482
erythrocyte osmotic resistance (abst) 506
exercise, pre-dialytic uremia (abst) 504
hemodialysis, hormone changes (abst) 1468
hemodialysis, iron (abst) 496
hemodialysis (abst) 504, 1458
hemodynamics (abst) 505
hypertension (abst) 495
mRNA regulation and cAMP 1581
parathyroid hormone, noninflammatory ARF (abst)... 488
porphyria cutanea tarda (abst) 1443
preuremia (abst) 504
subcutaneous (abst) 506
transplantation (abst) 507, 509
Essential fatty acid depletion, glomerulonephritis 1245
Essential hypertension and ESRD 36:S-33
European Hantavirus nephropathy (abst) 1431
Excretion
albumin, pregnancy (abst) 1437
sodium, cerebral regulation of thirst 37:S-102
sodium, tubular Na-K-ATPase 37:S-1 18
urinary angiotensin (abst) 1435
urinary protein, normal individuals (abst) 1437
Exercise
proteinuria, ACE inhibitors, IDDM (abst) 492
uninephrectomy, renal function (abst) 479
Extracellular matrix
binding of LDL 1161
cellular responses to 632
development 657
epithelial organ morphogenesis 629
graft-versus-host disease (abst) 700
during nephrogenesis 641
production regulated by TGF-/3l 1213
synthesis (abst) 700
synthesis and morphine 1560
transforming growth factor-p 557
Extracellular volume, parathyroid hormone (abst) 1443
Extracorporeal shock wave lithotripsy (abst) 1473
Familial Mediterranean fever 414
Fanconi syndrome (abst) 1453
Felodipine
acute renal failure 36:S-94
angiotensin II, natriuresis 36:S-73
compared with enalapril 36:S-78
with cyclosporine after transplant 36:S-82
renal function 36:S-54, 36:S-lOO, 36:S-106, 36:S-l10
Ferrioxamine, removal in dialysis 1400
Ferritin levels, hemodialysis (abst) 1472
Fibroblasts, tubulointerstitial 14
Fibronectin
laminin, epithelial cells (abst) 701
production, mesangial cell 396
synthesis, gene transcription (abst) 706
synthesis, TGF-p, MC cultures (abst) 703
Filopedia, function of 665
Fish oil supplementation, hemodialysis patients (abst). . 1446
Fistula dysfunction in rapid hemodialysis 1292
Fluoride
aluminum-induced bone disease 1340
flux in rabbit CCD 342
Focal segmental glomerulosclerosis
lovastatin (abst) 1453
mesangial expression of ICAM-1 951
in MGN 428
Folate binding protein in proximal tubule 50
Fosinopril, nifedipine, in diabetic rats 891
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Furosemide
infusion, lithium (abst) 1430
papillary osmolality (abst) 494
Gadolinium-DTPA, glomerular filtration rate 1595
Ganglioside, expression in renal cortex 1638
Gemfibrozil, hyperlipidemia, CAPD (abst) 1456
Gentamicin nephrotoxicity (abst) 1462
Glomerular basement membrane
diabetic nephropathy, HSPG 1070
diabetic nephropathy (abst) 484, 703
HSPG antibodies and proteinuria 115
Glomerular cells
development 657
proliferation (abst) 297, 701






aminopeptidases A and N 1571
cell density, growth regulation (abst) 698
matrix production, TGF-pl regulation 1213
mRNa 72kDa type IV collagenases (abst) 704
Glomerular filtration rate
calcium antagonists 36:S-43
contrast media as clinical marker (abst) 500
dietary protein, hyperglycemia 1620
estimation by intraperitoneal mTc DTPA 450
hyperfiltration predicts nephropathy 822
IgA nephropathy (abst) 512
kallikrein, renin gene expression 789
measurement, gadolinium-DTPA 1595
measurement, iothalamate 1081
measurement, rapid in small animals 435
measurement, subcutaneous infusion 1701
measurement (abst) 511
newly-presenting NIDDM 829
serotoninergic hepatorenal reflex (abst) 496
Glomerular hemodynamics
platelet activating factor (abst) 495
progressive renal disease 36:S-8
Glomerular hyperfiltration (abst) 494
Glomerular immune deposits 1690
Glomerular lesions, wire-loop 65
Glomerular mesangial cells
collagen production (abst) 1452
glucose, insulin, somatostatin (abst) 702
identification, in vivo, in vitro (abst) 696
immune complex, collagen production (abst) 1462
interleukin-6 (abst) 698
Glomerular mesangial matrix
glycoprotein synthesis (abst) 705
turnover and proteinases 671
Glomerular N-deacetylase in diabetes 763
Glomerular permselectivity 310




Glomerular thrombomodulin activity 1170
Glomerular thromboxane receptors in diabetes 992
Glomej-ular tissue factor, thromboxane synthesis 361
Glomerular vascular components, parietal podocyte .... 211
Glomerular volume, measurement in IDDM 1085
Glomeruli
electron microscopy in NIDDM 749
isolated perfused, renin release in 275
Glomerulonephritis
l5-S-HETE antagonizes LTB4 1155
acute extracapillary necrotic (abst) 511
anti-glomerular basement membrane antibody (abst) . 1452
apoptosis 607
autoimmune 5
CSb-9 complement proteins (abst) 496
cytokines, growth factors (abst) 497
differential diagnosis (abst) 484
essential fatty acid depletion 1245
focal glomeruloscierosis 428
hemodynamics, proteinuria (abst) 483
hepatitis B virus associated, pathology (abst) 1453
histological changes, biopsy (abst) 494
idiopathic necrotizing 375
integrins (abst) 480, 701




polyanion charge and RBC (abst) 487
treatment with TGF-f3 antagonists 566
Glomerulopathy, collagen type III (abst) 1445
Glomerulosclerosis
cholesterol, hypertension 1254
glomerular cell proliferation and PDGF 297
graft-versus-host disease (abst) 700
idiopathic membranous glomerulonephritis 428
mesangial expression, ICAM-1 in FSGS 951
nifedipine (abst) 485
prevention with TGF—f3 antagonists 566
Gluconeogenesis, cisplatin-induced alterations 73
Glucose
glornerular redox changes 778
heparan sulfate proteoglycan synthesis (abst) 705
intolerance, l,25(OH)2D3, hemodialysis 1049
mesangial cell fibronectin production 396
TGF-f3 gene in proximal tubule 107
transport, cadmium toxicity (abst) 1451
Glutamine and ammonia formation (abst) 484
Glycolysis and vasorelaxant effect of acetate 166
Glycoprotein synthesis (abst) 705
Glycosaminoglycans
calcium oxalate urolithiasis 149
IGF enhanced biosynthesis 1262
GM-CSF in renal epithelial cells (abst) 482




glomei-ulosclerosis, extracellular matrix (abst) 700
lupus nephritis 5





growth retarded uremic children (abst) 1461
secretion in CR1 356
11-HSD, regulation of sodium balance 37:S-114
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25-hydroxyvitamin D
nephrotic syndrome, children (abst) 1450
Hantavirus nephropathy (abst) 1431
HCV infection in CAPD (abst) 483
Heart rate, spectral analysis 37:S-14
Heat-shock protein 73-kDa, renal localization 1204
Hematuria, children (abst) 1471
Hemodiafiltration
hemodialysis comparison 1035
multipurpose system (abst) 501
Hemodialysis
aluminoxamine, ferrioxamine removal 1400
aluminum bone disease 1374
amyloidosis pathogenesis (abst) 486
calcium, vitamin D therapy (abst) 501
calcium carbonate, phosphate binding (abst) 1456
carnitine metabolism 1613
cellular immunology (abst) 495
coagulation inhibitors (abst) 1470
cytokine production, Nephrology Forum 683
diabetic patients, clinical features (abst) 1448
elderly patients (abst) 502
EPO therapy, hormone changes (abst) 1468
EPO therapy, iron (abst) 496
EPO therapy, life quality (abst) 504
EPO therapy, porphyria cutanea tarda (abst) 1443
EPO therapy, RBC (abst) 494
EPO therapy (abst) 505, 506, 1458
excessive thirst (abst) 1446
fish oil supplements (abst) 1446
hemodiafiltration, comparison 1035
heparin therapy (abst) 502
hepatitis C risk factors 1055
hippuric acid excretion (abst) 1433
hyperparathyroidism (abst) 491
hypoxemia, fibrinolytic system (abst) 1472
impaired platelet TSP release (abst) 482
leukocyte counts, membrane type (abst) 479
lipid peroxidation risk (abst) 480
lipoprotein abnormalities 1394
measurement of dry weight 440
morbidity, mortality factors 1029
non-occlusive mesenteric obstruction (abst) 498
1 ,25(OH)2D3, glucose intolerance 1049
peripheral venous compliance 1041
prescription, delivery 1023
rapid, fistula dysfunction 1292
recirculation in (abst) 1455
survival rates, blood pressure control 1286
survival rates (abst) 1456
thyroid function (abst) 1469
underweight patients, CRF (abst) 1465
venous/arterial systems, plasma volume (abst) 1435




dopaminergic modulation (abst) 1445
erythropoietin therapy (abst) 505
felodipine, enalapril compared 36:S-78
glomerular, progressive renal disease 36:S-8
glomerulonephritis, ACE inhibition (abst) 483
high volume hemofiltration (abst) 1434
PKD 206
pre-dialysis, anemia, EPO therapy 384
proteinuria, beta-blockers, ACE inhibitors 1297
venous compliance, ultrafiltration (abst) 1434
Hemofiltration, endotoxin shock hemodynamics (abst) . 1434
Hemoperfusion, aluminoxamine, ferrioxamine removal. 1400
Hemorrhagic fever renal syndrome (abst) 1454, 1455
Henoch-Schönlein purpura nephritis (abst) 1453
Henoch-Schonlein vasculitis (abst) 1468
Heparan sulfate
anti-GBM, proteinuria 115
diabetic nephropathy 1070, 1432 (abst)
proteoglycan, synthesis (abst) 705
Hepatitis B
glomerulonephritis, pathology (abst) 1453
recombinant vaccine, nonresponders (abst) 1447
transplantation (abst) 1466
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